Table 2.
Cox regression analysis of biochemical recurrence in patients treated with post-prostatectomy radiotherapy
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (years) | 0.974 (0.944–1.005) | 0.099 | 0.978 (0.943–1.014) | 0.228 |
| BMI (kg/m2) | 0.942 (0.871–1.018) | 0.131 | ||
| Pre-operative PSA (ng/mL) | ||||
| < 20.00 | (reference) | (reference) | ||
| ≥ 20.00 | 1.640 (1.032–2.608) | 0.036 | 1.112 (0.625–1.976) | 0.719 |
| Pre-radiotherapy PSA (ng/mL) | ||||
| < 1.00 | (reference) | (reference) | ||
| ≥ 1.00 | 2.122 (1.288–3.497) | 0.003 | 4.383 (1.797–10.688) | 0.001 |
| Pathologic Gleason score | ||||
| ≤ 7 | (reference) | |||
| ≥ 8 | 1.393 (0.897–2.163) | 0.140 | ||
| Pathologic T stage | ||||
| ≤ pT2 | (reference) | |||
| ≥ pT3 | 1.272 (0.798–2.029) | 0.312 | ||
| Pathologic N stage | ||||
| pN0 or pNx | (reference) | |||
| pN1 | 0.498 (0.157–1.579) | 0.236 | ||
| Tumor volume (%) | ||||
| < 10.0 | (reference) | |||
| ≥ 10.0 | 0.939 (0.600–1.469) | 0.783 | ||
| Surgical margin tumor involvement | ||||
| Negative | (reference) | |||
| Positive | 0.815 (0.525–1.266) | 0.363 | ||
| Radiation dose (Gy) | ||||
| < 66.0 | (reference) | |||
| ≥ 66.0 | 0.770 (0.406–1.461) | 0.424 | ||
| Testosterone nadir after RP (ng/mL) | 1.088 (0.948–1.248) | 0.229 | ||
| Duration of unrecovered testosterone level (months) | 0.984 (0.970–0.998) | 0.031 | 0.991 (0.971–1.011) | 0.361 |
| Concurrent ADT | ||||
| No | (reference) | (reference) | ||
| Yes | 0.564 (0.352–0.905) | 0.018 | 0.381 (0.157–0.927) | 0.034 |
HR hazard ratio, CI confidence interval, BMI body mass index, PSA prostate specific antigen, RP radical prostatectomy, ADT androgen deprivation therapy